Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


With Resolution of Fee-Sharing Dispute, Settlement Funding is Now Available to Avandia Plaintiffs' Attorneys

CRESSKILL, N.J., Feb. 14, 2013 /PRNewswire/ -- Attorneys representing plaintiffs suing GlaxoSmithKline (GSK) over the drug Avandia's side effects have resolved their dispute about sharing fees of $142 million. Over 50,000 lawsuits were filed in US state and federal courts citing GlaxoSmithKline's failure to inform type-2-diabetes patients about Avandia's potentially life-threatening side effects: heart attack and failure, stroke, bone fractures, vision loss, and death. The litigation has taken over ten years, with the lead attorneys alone logging more than 60,000 hours. Yet none of the plaintiffs' attorneys have received any compensation for their time or out-of-pocket expenses. RD Legal Funding is now making immediate post-settlement financing available to ease the Avandia plaintiffs' attorneys' financial burdens. 

(Photo: http://photos.prnewswire.com/prnh/20110803/NY45278LOGO)

The FDA approved the use of rosiglitazone—marketed as Avandia—for the treatment of type-2-diabetes in 1999. Tens of millions of prescriptions were written for the drug which may have caused between 60,000 and 200,000 heart attacks and deaths due to cardiovascular problems in the US alone.

  • 2001: GSK receives an FDA reprimand letter regarding false and misleading comments made by sales representatives about Avandia to an undercover investigator.
  • 2005: GSK's draft analysis of Avandia clinical data indicates heart risks. The company modifies Avandia labels, but the warnings are not prominently displayed and do not adequately convey potential health hazards.
  • 2007:  The New England Journal of Medicine reports that Avandia users face a 43 percent higher risk of heart attack or other cardiovascular events and over 60% increase in the risk of cardiovascular death. Avandia profits in 2007 are $3.2 billion.
  • 2007: Congressional hearings review when information about Avandia heart attack risks was available and why it was not disclosed to the public earlier. The FDA mandates a black box warning about Avandia heart attack risks.
  • 2008: An FDA report implicates Avandia in an estimated 83,000 heart attacks.
  • September 2010: Avandia is banned in several European countries but remains on the US market.
  • 2010: GSK pays a $2.36 billion charge to settle 10,000 of 13,000 Avandia US civil lawsuits, investigations over its antidepressant Paxil, and manufacturing problems in its Puerto Rico plant.
  • November 2011: GSK agrees to pay the US government $3 billion to resolve civil and criminal investigations alleging that the company had paid doctors and manipulated medical research to promote Avandia. A mediator is appointed to resolve the bulk of the pending MDL cases.
  • January 2012: A committee of eight Avandia plaintiffs' attorneys is charged with drafting the fee allocation plan for 58 lawyers and firms, with the total amount to be distributed set at 6.25 percent of the total settlement.
  • July 2012: GSK pleads guilty to withholding safety data on Avandia.
  • November 2012: GSK agrees to pay $90 million to settle the claims of 37 states and the District of Columbia.
  • November 2012: The committee submits its fee-sharing agreement which is disputed by nine attorneys. Bruce P. Merenstein is appointed as special master. 
  • January 22, 2013: A modified plan, agreed to by the nine objectors, is filed in PA federal court.

Avandia plaintiffs' attorneys are urged to contact RD Legal Funding, whose unique fee acceleration program will provide them with settlement financing within several days, with no monthly interest or principal payments, as well as no upfront points or fees. No payment of any kind is required until the attorney's settlement fee is received. RD Legal Funding is one of the nation's leading providers of post-settlement financing. For more information call 800-565-5177 or visit http://www.legalfunding.com.

SOURCES:
http://topics.nytimes.com/top/news/health/diseasesconditionsandhealthtopics/avandiadrug/index.html
http://www.drugwatch.com/avandia/lawsuit.php
http://www.bloomberg.com/news/2013-01-18/glaxo-accord-said-to-spur-lawyer-fight-over-fees.html
http://www.legalfunding.com/blog/settlement-funding-for-avandia-plaintiffs-attorneys/

SOURCE RD Legal Funding

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
When people think of mainframes, they typically envision ancient, obsolete technology running arcane spaghetti code – systems that IT management would love to retire if only they could free themselves from the clutches of legacy. While there is an element of truth in this perspectiv...
Last week as I was writing Amazon Declares War on VMware, VMware was preparing to announce the acquisition of a pro services team to aid in cloud migration (see coverage in CRN): VMware Acquires Professional Services Firm To Boost Cloud Migration, DevOps Expertise. You can get my thoug...
Change is constant, and over the last decade the nexus of two trends in particular has transformed the enterprise. Mobile technology and cloud software are fundamentally changing the way we interact internally within businesses, and externally with partners and customers. Never befor...
So congratulations, somehow you've managed to wangle your way onto one of the many DevOps conferences being held around the world. Why not you might say? DevOps is not only hot it's the approach many enterprises are now exploring as the means to help accelerate the delivery of high qua...
What does the data landscape look like at Facebook with its 1.3 billion users across the globe? They classify small data referring to OLTP-like queries that process and retrieve a small amount of data, usually 1-1000 objects requested by their … MORE »
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE


ADVERTISE   |   MAGAZINE SUBSCRIPTIONS   |   FREE BREAKING-NEWSLETTERS!   |   SYS-CON.TV   |   BLOG-N-PLAY!   |   WEBCAST   |   EDUCATION   |   RESEARCH

.NET Developer's Journal - .NETDJ   |   ColdFusion Developer's Journal - CFDJ   |   Eclipse Developer's Journal - EDJ   |   Enterprise Open Source Magazine - EOS
Open Web Developer's Journal - OPENWEB   |   iPhone Developer's Journal - iPHONE   |   Virtualization - Virtualization   |   Java Developer's Journal - JDJ   |   Linux.SYS-CON.com
PowerBuilder Developer's Journal - PBDJ   |   SEO / SEM Journal - SJ   |   SOAWorld Magazine - SOAWM   |   IT Solutions Guide - ITSG   |   Symbian Developer's Journal - SDJ
WebLogic Developer's Journal - WLDJ   |   WebSphere Journal - WJ   |   Wireless Business & Technology - WBT   |   XML-Journal - XMLJ   |   Internet Video - iTV
Flex Developer's Journal - Flex   |   AJAXWorld Magazine - AWM   |   Silverlight Developer's Journal - SLDJ   |   PHP.SYS-CON.com   |   Web 2.0 Journal - WEB2
Apache   |   CMS   |   CRM   |   HP   |   Oracle Journal   |   Perl   |   Python   |   Red Hat   |   Ruby on Rails   |   SAP   |   SaaS

SYS-CON MEDIA:   ABOUT US   |   CONTACT US   |   COMPANY NEWS   |   CAREERS   |   SITE MAP
SYS-CON EVENTS  |  AJAXWorld Conference & Expo  |  iPhone Developer Summit  |  OpenWeb Developer Summit  |  SOA World Conference & Expo  |  Virtualization Conference & Expo
INTERNATIONAL SITES:   India  |  U.K.  |  Canada  |  Germany  |  France  |  Australia  |  Italy  |  Spain  |  Netherlands  |  Brazil  |  Belgium
 Terms of Use & Our Privacy Statement     About Newsfeeds / Video Feeds
Copyright ©1994-2008 SYS-CON Publications, Inc. All Rights Reserved. All marks are trademarks of SYS-CON Media.
Reproduction in whole or in part in any form or medium without express written permission of SYS-CON Publications, Inc. is prohibited.